Leventhal Quoted on Court’s Reversal of Reduction in Medi-Cal Outpatient Rates
07 August 2017
Partner Robert Leventhal was quoted in a San Francisco Chronicle article, “SF Court Reverses Approval on Lowered Medi-Cal Outpatient Rates,” covering a 9th U.S. Circuit Court of Appeals decision overturning a reduction in Medi-Cal reimbursement rates to California hospitals for outpatient services during the recession.
Leventhal, who represented 57 hospitals in a challenge to the temporary rate reduction, said the ruling could affect future Medi-Cal payments as well.
“This case sets a standard for what has to be taken into account” in setting payment levels to hospitals for outpatient services for Medi-Cal patients, he said.
Leventhal, who represented 57 hospitals in a challenge to the temporary rate reduction, said the ruling could affect future Medi-Cal payments as well.
“This case sets a standard for what has to be taken into account” in setting payment levels to hospitals for outpatient services for Medi-Cal patients, he said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”